We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Animalcare Group Plc | ANCR | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 1.00 | 0.42% | 237.00 | 14:50:30 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 236.00 | 236.00 | 237.00 | 237.00 | 236.00 |
| Industry Sector |
|---|
| FOOD PRODUCERS |
| Announcement Date | Type | Currency | Dividend Amount | Ex Date | Record Date | Payment Date |
|---|---|---|---|---|---|---|
| 24/09/2024 | Interim | GBP | 0.02 | 17/10/2024 | 18/10/2024 | 15/11/2024 |
| 09/04/2024 | Final | GBP | 0.03 | 20/06/2024 | 21/06/2024 | 19/07/2024 |
| 26/09/2023 | Interim | GBP | 0.02 | 19/10/2023 | 20/10/2023 | 17/11/2023 |
| 28/03/2023 | Final | GBP | 0.024 | 15/06/2023 | 16/06/2023 | 14/07/2023 |
| 27/09/2022 | Interim | GBP | 0.02 | 20/10/2022 | 21/10/2022 | 18/11/2022 |
| 29/03/2022 | Final | GBP | 0.024 | 09/06/2022 | 10/06/2022 | 08/07/2022 |
| 28/09/2021 | Interim | GBP | 0.02 | 21/10/2021 | 22/10/2021 | 19/11/2021 |
| 30/03/2021 | Final | GBP | 0.02 | 03/06/2021 | 04/06/2021 | 02/07/2021 |
| 29/09/2020 | Interim | GBP | 0.02 | 22/10/2020 | 23/10/2020 | 20/11/2020 |
| Top Posts |
|---|
Posted at 04/1/2025 17:30 by p1nkfish Yes, will relook at 260 and 359.Yes, could fly, in no rush. Sensible management building for the long term. Was surprised the price they achieved for the tagging side of the business, was an excellent move. A bit overweight ANCR but see no reason to trim it, one to ride to see what happens. It also has something the likes of Zoetis need, decent growth potential with margins to be proud of along with increased geographic spread after recent acquisition. ZTS are OK geographically but a bit stale. Held them a few years back, Decent run 2018 for 3 years. They are also very active in Equine but ANCR would currently be noise to them as an acquisition. That may change in a few years, at a much higher price. |
Posted at 04/1/2025 14:46 by simon gordon EI,ANCR now has the rights to sell Plaqtiv throughout Europe all channels, Amazon and the likes of Viovet should see some good growth. 36%+ in H1, and it sounds like they are going to put marketing spend behind it. I see Scott Galloway has Shein down as the IPO of the year - 7.15 minute mark: Raspberry Pi has rocked hard since flotation. |
Posted at 04/1/2025 13:49 by simon gordon EI,Latest data is in the fundraise RNS - 3/12/24: |
Posted at 12/12/2024 16:19 by simon gordon Pharmashots - 12/12/24:Top 20 Animal Health Companies of 2024 -The WHO’s One Health policy is driving innovation in animal health, emphasizing the intersection of human, animal, and environmental care -The global animal health market, valued at $62.4B in 2023, is expected to grow at a CAGR of 9%, reaching $114B by 2030 -PharmaShots presents a comprehensive report on the Top 20 Animal Health Companies of 2024, led by Zoetis ($8.54B), MSD Animal Health ($5.62B), and Boehringer Ingelheim ($5.21B), based on their strong revenue performances Continued... |
Posted at 07/12/2024 16:26 by simon gordon Is this the deal of the decade or is there a catch?Panmure - 16/10/24: In order to provide a sense of what this strategy could do for Animalcare, we modelled a base case scenario that makes the following assumptions: Geography – Animalcare closes a deal in January 2025, spending £40m at 17.5x EBITDA to acquire a European veterinary pharmaceutical with EBITDA margins of 15%...... ANCR - 3/12/24: A highly profitable business with EBITDA of A$11.0 million and an EBITDA margin of 48% in FY24, expected to deliver significant earnings accretion in 2025 Acquisition multiple of 10.9x adjusted EBITDA (year ended 30 June 2024) Acquisition expected to be materially earnings accretive - at least 20% in FY25 |
Posted at 04/12/2024 18:08 by simon gordon If — and it's a significant "if" — the equine VHH (Variable Heavy Chain antibody) proves successful it could drive a re-rating of the share, potentially up to 30x. Christopher Mills, CEO of Harwood Capital, mentioned during the July 2024 Vox Markets webinar that he anticipates news on the equine VHH probably by the end of 2024.ANCR on the Randlab acquisition - 3/12/24: Provides the opportunity to maximise the potential of Animalcare's current equine developments (e.g. VHH antibody programme) and enhances future equine partnering opportunities alongside other commercial and new product development synergies |
Posted at 11/4/2024 14:23 by p1nkfish Potentially another $5M approx USD from exit of equity in STEM whilst ANCR allowed distribution access to all channels in Europe and UK. DECHRA taking it.Just found the analysts presentation on the web, page 16, the have approx 7 products or companies in discussion out of more than 450 to begin with. Homing in on target(s) and now have the cash and credit facilities to pull the trigger(s). I like the look of the way they have a plan and focused on executing it. |
Posted at 13/3/2024 16:17 by 1c3479z have to agree that ANCR least likely to be affected by the CMA enquiry, just putting it out as a conjecture, if the whole vet industry is to be brought to heal by the authorities. Not trying to scare at all as ANCR is a family holding, albeit small, sadly, in comparison with my own holding in CVSG which is much more in the firing line. |
Posted at 26/11/2021 12:55 by km18 From WealthOracleAM....Animalcare Limited founded in 1988 became the Animalcare Group in 2008. In July 2017 they made a reverse acquisition of Ecuphar NV, which is still casting a shadow over the share, as the share remains belowthe price before the transaction. Currently they are operating in 32 markets through 220 employees. ANCR is adopting a more organic approach towards growth, with focus on key therapy areas and new products development. This can be seen also in the financials with goodwill relatively flat over the years, but at quite high percentage of total assets – 51%, which has been impaired recently. Other than the “underapprecia |
Posted at 08/7/2021 13:28 by pugugly Secondary placing - Hit share price very hard. Views?8 July 2021. Animalcare Group plc (AIM: ANCR), the international animal health business, announces that it has been notified by Ecuphar Invest NV ("Seller") of its intention to sell up to 13,857,213 ordinary shares in the capital of the Company (the "Placing" and the "Placing Shares") at a price of 285 pence per Placing Share ("Placing Price"). The Placing Price represents a c. 20 per cent. discount to the closing price of 356 pence per share on 7 July 2021 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
